Chimeric complement inhibitor proteins
AssigneeAlexion Pharmaceuticals, Inc.
InventorsWilliam L. Fodor, Scott Rollins, Stephen P. Squinto
Life of this patent
Estimating the term…
Abstract
Chimeric complement inhibitor proteins are provided which include a first functional domain (first amino acid sequence) having C3 inhibitory activity and a second functional domain (second amino acid sequence) having C5b-9 inhibitory activity. The first functional domain is amino terminal to the second functional domain. In this way, the chimeric protein exhibits both C3 and C5b-9 inhibitory activity. The other orientation, i.e., the orientation in which the second amino acid sequence is amino terminal to the first amino acid sequence, only produces C3 inhibitory activity. Nucleic acid molecules encoding such proteins are also provided.
Claims5
A chimeric complement inhibitor protein comprising a first functional domain having C3 inhibitory activity and a second functional domain having C5b-9 inhibitory activity;
- wherein
- (a) said first functional domain is amino terminal to said second functional domain;
- (b) said first functional domain comprises at least a portion of a naturally occurring C3 inhibitor protein;
- (c) said second functional domain comprises at least a portion of a naturally occurring C5b-9 inhibitor protein;
- and
- (d) the protein has complement inhibitory activity against human complement.
Dependencies are inferred from the claim text.